MARKET

SILO

SILO

Silo Pharma Inc
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.150
+0.010
+7.07%
Closed 15:57 08/10 EDT
OPEN
0.137
PREV CLOSE
0.140
HIGH
0.150
LOW
0.133
VOLUME
158.25K
TURNOVER
22.22K
52 WEEK HIGH
0.390
52 WEEK LOW
0.090
MARKET CAP
14.90M
P/E (TTM)
3.561
1D
5D
1M
3M
1Y
5Y
Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical compan...
GlobeNewswire · 07/27 12:15
Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduce...
GlobeNewswire · 07/12 15:23
Silo Pharma Expands License Agreement and Patent Portfolio
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a ...
GlobeNewswire · 06/23 12:05
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study
Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, to...
GlobeNewswire · 05/19 12:11
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest ep...
GlobeNewswire · 05/18 12:17
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies.ENGLEWOOD CLIFFS, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelic...
GlobeNewswire · 04/20 12:10
Silo Pharma contracts Frontage Labs for pharmacokinetic study in animals
Silo Pharma (OTCQB:SILO) signed an agreement with contract research organization Frontage Laboratories for a pharmacokinetic study in animals. A pharmacokinetic study involves observing how a new drug or substance affects trial
Seekingalpha · 03/31 16:56
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
IND Enabling Study to prepare Silo Pharma Homing Peptides for ClinicENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeuti...
GlobeNewswire · 03/31 12:10
More
No Data
Learn about the latest financial forecast of SILO. Analyze the recent business situations of Silo Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.30%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/President/Chief Financial Officer/Chief Compliance Officer/Director
Eric Weisblum
Director
Wayne Linsley
Independent Director
Kevin Munoz
No Data
No Data
About SILO
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on merging traditional therapeutics with psychedelic research for people suffering from indications, including depression, post-traumatic stress disorder (PTSD), Parkinson's disease and other neurological disorders. The Company is focused on the use of psilocybin as a therapeutic.

Webull offers kinds of Silo Pharma Inc stock information, including OTCMQB:SILO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SILO stock methods without spending real money on the virtual paper trading platform.